

Company Factsheet

February 2024

Updated: 22 February 2024

hikma.

Company description

Hikma is a multinational pharmaceutical company. Listed on the London Stock Exchange, we are a global company with a local presence across North America, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products.

Acting responsibly

At Hikma, we strive to put better health within reach, every day and make a difference to people's lives.

We have a duty to act responsibly: for our people, patients, communities and the planet. We have identified four focus areas where we can drive positive impact.



Key group financials

(Year end December 2023)

Core revenue
2023: \$2,875m
2022: \$2,517m

Core operating profit
2023: \$707m
2022: \$596m

Core EBITDA
2023: \$811m
2022: \$695m


Core basic EPS
2023: 223c
2022: 181c

DPS
2023: 72c
2022: 56c

Net debt to EBITDA
2023: 1.2x
2022: 1.5x

Core results show the underlying performance of the Group, excluding exceptional items.

% Group core revenue



Strategy

We aim to deliver consistent and profitable growth by putting better health within reach every day, creating high-quality medicines and making them accessible for patients around the world. We do this by focusing on three strategic pillars: Strive for excellence, Diversify and differentiate and People and responsibility.



Injectables

We supply hospitals across our markets with generic injectables, supported by our manufacturing facilities in the US, Europe and MENA.



Branded


We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.



Generics

We supply oral and other non-injectable generic and specialty branded products in the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.

Company strengths



Unique and diversified business model



Injectables 42%
Branded 25%
Generics 33%



Strong market position

#3 generic injectable manufacturer in the US¹
#2 pharmaceutical company in MENA²



Commitment to quality

13 US FDA inspected plants
12 EMA-inspected plants



Large and growing portfolio and pipeline

760+ Products
250+ Projects in our pipeline



17.7%
ROIC

Return on invested capital


Return on invested capital is calculated as core operating profit after interest and tax divided by invested capital (calculated as total equity plus net debt).

1. Source: IQVIA MAT through December 2023, generic injectable volumes by eache, excluding branded generics and Becton Dickinson
2. Source: Based on internal analysis by Hikma using IQVIA MIDAS* Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Injectables



Core Revenue



Core Op. Profit



Key focus areas

- Continue to grow our base business through our scale and strength of customer relationships
- Launch between 10 to 15 products in the US every year
- Strengthen MENA and expand EU

Products: Includes anti-infectives, pain management, cardiovascular, oncology

Customers: Includes hospitals, Group Purchasing Organisations, Civica Rx

Capabilities: Includes sterile liquid, powder, lyophilised and cytotoxic products, in a broad range of forms, including vials, ampules, bags and prefilled syringes, manufactured in facilities in the US, Portugal, Germany, Italy and MENA

Branded



Core Revenue



Core Op. Profit



Key focus areas

- We operate in 17 markets across the MENA region
R&D is focused on key markets and high value therapeutic areas, with an increasing focus on chronic illnesses
- Partnerships are a key contributor to this business and we work hard to maintain our partner of choice status with global innovative pharma companies

Products: Broad portfolio of branded generics and in-licensed products – we are the partner of choice in the region

Customers: Pharmacies and hospitals across the region

Capabilities: Manufacturing facilities in seven countries, many of which are both locally approved, and US FDA and EMA-approved. 2,000 sales representatives and support staff across our 17 markets

Generics



Core Revenue



Core Op. Profit



Key focus areas

- Differentiation – offer broad portfolio of differentiated products, including nasal sprays and respiratory
- Quality and operational efficiencies – world-class FDA-inspected facilities
- Pipeline – focus on adding complex and specialty products through R&D and partnerships

Products: Broad product portfolio encompassing oral solids and liquids and leader in US prescription nasal sprays

Customers: 90% of retail generics bought by three customer consortia

Capabilities: State of the art facility in Columbus Ohio, as well as US FDA-inspected facilities in Saudi Arabia and Jordan

Company information

Chief Executive Officer: **Riad Mishlawi**
Chief Financial Officer: **Khalid Nabils**

Hikma Pharmaceuticals PLC
1 New Burlington Place
London W1S 2HR

Contacts

See www.hikma.com for contact forms